New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
Allogeneic SCT Benefits Children and Adolescents With Relapsed Anaplastic Large Cell Lymphoma

Allogeneic SCT Benefits Children and Adolescents With Relapsed Anaplastic Large Cell Lymphoma

December 23, 2020Katie KoskoDecember 23, 2020 — Findings from the International, Prospective ALCL-Relapse trial showed that allogeneic SCT after reinduction chemotherapy can lead to survival improveme
World medicine November 20,2023
Allogeneic SCT Benefits Children and Adolescents With Relapsed Anaplastic Large Cell Lymphoma

Allogeneic SCT Benefits Children and Adolescents With Relapsed Anaplastic Large Cell Lymphoma

December 23, 2020Katie KoskoDecember 23, 2020 — Findings from the International, Prospective ALCL-Relapse trial showed that allogeneic SCT after reinduction chemotherapy can lead to survival improveme
World medicine November 20,2023
Stage 4 Non-Small Cell Lung Cancer: Staging, Treatment, Prognosis

Stage 4 Non-Small Cell Lung Cancer: Staging, Treatment, Prognosis

NSCLC is the Most Common Type of Lung CancerByLynne Eldridge, MDUpdated on May 05, 2023Medically reviewed byLindsay Cook, PharmDStage 4non-small cell lung cancer(NS
World medicine November 20,2023
Stage 4 Non-Small Cell Lung Cancer: Staging, Treatment, Prognosis

Stage 4 Non-Small Cell Lung Cancer: Staging, Treatment, Prognosis

NSCLC is the Most Common Type of Lung CancerByLynne Eldridge, MDUpdated on May 05, 2023Medically reviewed byLindsay Cook, PharmDStage 4non-small cell lung cancer(NS
World medicine November 20,2023
Designer DNA Therapeutic Wipes Out Cancer Stem Cells, Treats Multiple Myeloma in Mice

Designer DNA Therapeutic Wipes Out Cancer Stem Cells, Treats Multiple Myeloma in Mice

April 23, 2021Heather Buschman, PhDStudy supports launch of Phase I clinical trial to test a designer DNA agent — an antisense oligonucleotide that targets a gene called IRF4 — in patients with multip
World medicine November 20,2023
Designer DNA Therapeutic Wipes Out Cancer Stem Cells, Treats Multiple Myeloma in Mice

Designer DNA Therapeutic Wipes Out Cancer Stem Cells, Treats Multiple Myeloma in Mice

April 23, 2021Heather Buschman, PhDStudy supports launch of Phase I clinical trial to test a designer DNA agent — an antisense oligonucleotide that targets a gene called IRF4 — in patients with multip
World medicine November 20,2023
Total Body Irradiation Plus Etoposide Improves Survival in Select Transplant-Eligible Pediatric High-Risk ALL

Total Body Irradiation Plus Etoposide Improves Survival in Select Transplant-Eligible Pediatric High-Risk ALL

February 25, 2021Hayley VirgilTotal body irradiation plus etoposide prior to hematopoietic stem cell transplantation resulted in improved overall survival and a lower risk of relapse in pediatric pati
World medicine November 20,2023
Total Body Irradiation Plus Etoposide Improves Survival in Select Transplant-Eligible Pediatric High-Risk ALL

Total Body Irradiation Plus Etoposide Improves Survival in Select Transplant-Eligible Pediatric High-Risk ALL

February 25, 2021Hayley VirgilTotal body irradiation plus etoposide prior to hematopoietic stem cell transplantation resulted in improved overall survival and a lower risk of relapse in pediatric pati
World medicine November 20,2023
Intensified Daratumumab Plus CVRd and Bortezomib-Augmented ASCT Demonstrates Promise in Ultra High–Risk Multiple Myeloma

Intensified Daratumumab Plus CVRd and Bortezomib-Augmented ASCT Demonstrates Promise in Ultra High–Risk Multiple Myeloma

June 11, 2021Audrey SternbergIntensified induction therapy with daratumumab in addition to cyclophosphamide, bortezomib, lenalidomide, and dexamethasone and bortezomib-augmented autologous stem cell t
World medicine November 20,2023
Intensified Daratumumab Plus CVRd and Bortezomib-Augmented ASCT Demonstrates Promise in Ultra High–Risk Multiple Myeloma

Intensified Daratumumab Plus CVRd and Bortezomib-Augmented ASCT Demonstrates Promise in Ultra High–Risk Multiple Myeloma

June 11, 2021Audrey SternbergIntensified induction therapy with daratumumab in addition to cyclophosphamide, bortezomib, lenalidomide, and dexamethasone and bortezomib-augmented autologous stem cell t
World medicine November 20,2023
Matched Sibling Donor Transplant Shows Improved OS at 2 Years in Relapsed/Refractory ALL

Matched Sibling Donor Transplant Shows Improved OS at 2 Years in Relapsed/Refractory ALL

April 26, 2022Gina MauroPatients with relapsed/refractory acute lymphoblastic leukemia who underwent matched sibling donor transplants had a significantly higher overall survival at 2 years compared w
World medicine November 20,2023
Matched Sibling Donor Transplant Shows Improved OS at 2 Years in Relapsed/Refractory ALL

Matched Sibling Donor Transplant Shows Improved OS at 2 Years in Relapsed/Refractory ALL

April 26, 2022Gina MauroPatients with relapsed/refractory acute lymphoblastic leukemia who underwent matched sibling donor transplants had a significantly higher overall survival at 2 years compared w
World medicine November 20,2023
Stem Cell Recipients Develop Robust Immunity Against SARS-CoV2 and Common Human Coronaviruses

Stem Cell Recipients Develop Robust Immunity Against SARS-CoV2 and Common Human Coronaviruses

February 8, 2021Kristie L. KahlFebruary 8, 2021 - These findings may have implications for patients with hematologic malignancies, suggesting the development of protective memory against SARS-CoV2 and
World medicine November 20,2023
Stem Cell Recipients Develop Robust Immunity Against SARS-CoV2 and Common Human Coronaviruses

Stem Cell Recipients Develop Robust Immunity Against SARS-CoV2 and Common Human Coronaviruses

February 8, 2021Kristie L. KahlFebruary 8, 2021 - These findings may have implications for patients with hematologic malignancies, suggesting the development of protective memory against SARS-CoV2 and
World medicine November 20,2023
Improved Induction Therapies Could Eliminate the Need for Transplant in Myeloma

Improved Induction Therapies Could Eliminate the Need for Transplant in Myeloma

September 16, 2020Hayley VirgilJeffrey Wolf, MD, discusses how induction therapies continue to improve the depth of response in patients with multiple myeloma and how it may be possible to eliminate t
World medicine November 20,2023
Improved Induction Therapies Could Eliminate the Need for Transplant in Myeloma

Improved Induction Therapies Could Eliminate the Need for Transplant in Myeloma

September 16, 2020Hayley VirgilJeffrey Wolf, MD, discusses how induction therapies continue to improve the depth of response in patients with multiple myeloma and how it may be possible to eliminate t
World medicine November 20,2023
Maintenance Daratumumab Improves PFS in Newly Diagnosed Transplant-Eligible Myeloma

Maintenance Daratumumab Improves PFS in Newly Diagnosed Transplant-Eligible Myeloma

October 22, 2020Gina MauroSingle-agent daratumumab as maintenance therapy improved progression-free survival compared with observation in patients with newly diagnosed multiple myeloma eligible for au
World medicine November 20,2023
Maintenance Daratumumab Improves PFS in Newly Diagnosed Transplant-Eligible Myeloma

Maintenance Daratumumab Improves PFS in Newly Diagnosed Transplant-Eligible Myeloma

October 22, 2020Gina MauroSingle-agent daratumumab as maintenance therapy improved progression-free survival compared with observation in patients with newly diagnosed multiple myeloma eligible for au
World medicine November 20,2023
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com